Starting Atypical Antipsychotics Increases Falls, Fractures
the Psychiatry Advisor take:
Older adults who start a new atypical antipsychotic medication have an increased risk for serious falls and fractures, according to a study published in JAMA Internal Medicine.
For patients aged ≥65 years, starting a new atypical antipsychotic increased their risk of falling by 53% and their risk of non-vertebral osteoporotic fracture by 50%.
The retrospective study included medical records from 200,000 Ontario residents. Patients who started taking one of three atypical antipsychotics – quetiapine (Seroquel), risperidone (Risperdal), or olanzapine (Zyprexa) – from 2003 to 2011 were matched with controls who did not take any of these medications. The researchers looked at fractures and falls that occurred up to 90 days after receiving the new prescription.
Patients who started on atypical antipsychotics had increased risks of hip fracture, non-vertebral osteoporotic fracture, and falls compared with controls. These risks were unrelated to the type of medication, the dosage, or whether the patient lived in a long-term care facility.
Out of those receiving atypical antipsychotics, 7.0% experienced fractures compared with 5.5% of controls. Additionally, 4.4% of those taking the medications experienced falls while only 2.9% of controls did.
The results add to evidence of safety concerns of using atypical antipsychotics in older adults; previous studies have already linked them to hypotension, sedation, and gait abnormalities.
For patients aged ≥65 years, starting a new atypical antipsychotic increased their risk of falling by 53%
Receiving a new prescription for an atypical antipsychotic medicine was associated with more serious falls and more fractures in a new retrospective cohort study.
Adults ages 65 and older who received a new prescription had a 53% increased risk of falling and a 50% increased risk of nonvertebral osteoporotic fracture, found the study. It was published as a research letter in JAMA Internal Medicine on Jan. 13, 2015, and was led by Lisa-Ann Fraser, MD, from the University of Western Ontario in Canada.
"These findings call into question the widespread off-label use of atypical antipsychotic medications and support increasing evidence of safety concerns regarding their use in older adults," Fraser and colleagues wrote.
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Duration of Untreated Depression Predicts Depression Severity
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV